Medical Concierge Centrum Medyczne | Warsaw, Poland

Research site

(Unclaimed)

Location

Polnej Rozy 6/U2, Warsaw, Mazovia, Poland

Site insights

Top conditions

Top treatments

Sasanlimab

Orforglipron

Semaglutide

Vepugratinib

LY3866288

allo-APZ2-OTS

Guselkumab

Nadofaragene

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

7 of 8 total trials

Locations recently updated

A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI)

The purpose of this study is to evaluate the efficacy and safety of guselkumab in participants with Crohn's disease.

Active, not recruiting

Crohn Disease

Drug: Guselkumab Dose 3

Drug: Placebo

A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight (RESTRAIN-SUI)

The GZPS master protocol will support two independent studies, J2A-MC-GZS1 and J2A-MC-GZS2. Each study will see how well and safely orforglipron work...

Enrolling

Urinary Incontinence,Stress

Drug: Placebo

Drug: Orforglipron

A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer (CREST)

The purpose of this study is to learn about the safety and effects of the study medicine (sasanlimab) in people with non-muscle invasive bladder canc...

Active, not recruiting

Non-muscle Invasive Bladder Cancer

Drug: Bacillus Calmette-Guerin

Drug: PF-06801591

A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract (FORAGER-2)

The purpose of this study is to test a new medicine, vepugratinib, in comparison with placebo, to see if it is safe and can help people with a bladde...

Enrolling

Urinary Bladder Neoplasms

Neoplasm Metastasis

Drug: Vepugratinib

Drug: EV

Locations recently updated

A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer (ABLE-22)

The pivotal phase 3 trial (rAd-IFN-CS 003) evaluating the efficacy of nadofaragene firadenovec showed that 55 (53.4%) of 103 subjects with CIS ± high...

Enrolling

Non-muscle Invasive Bladder Cancer With Carcinoma in Situ

Drug: Pembrolizumab

Drug: Docetaxel

Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Epidermolysis Bullosa (Phase III, Cross-over)

The aim of this clinical trial is to investigate the safety and efficacy of allo-APZ2-OTS administered intravenously to subjects with recessive dystr...

Active, not recruiting

Epidermolysis Bullosa

Drug: allo-APZ2-OTS

Drug: Placebo

Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)

Researchers are looking for new ways to treat high-risk non muscle invasive bladder cancer (HR NMIBC). NMIBC is cancer in the tissue that lines the i...

Active, not recruiting

High-risk Non-muscle Invasive Bladder Cancer

Biological: Pembrolizumab

Biological: BCG